Keywords: bad, news, bb, marimastat, after, disappointing, data

More bad news on BB's marimastat

Article | 13 February 2001

After disappointing data from five pivotal trials of British Biotech'soral matrix metalloproteinase inhibitor marimastat (Marketletters passim), the company has announced ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Schering Plough

Schering-Plough

Go to company listing